# bionews

# Key Takeaways from the 2024 Bionews Patient Survey: Living with Rare Disease

Living with a rare disease presents unique challenges. Every disease manifests differently, and the experiences of individuals vary greatly. By focusing on broad themes and shared challenges (*diagnostic and treatment journeys, and daily life experiences*), we can generate valuable data that will lead to more effective advocacy and support for all rare disease communities.

#### **About Rare Disease**

About 25-30 million Americans are living with rare diseases, which are conditions that affect a small percentage of the population. These diseases can be chronic, progressive, degenerative, and lifethreatening, and patients often have complex care needs. Many people living with rare diseases face challenges in diagnosis, treatment, and access to care.

#### **About the Survey**

Bionews conducted an important nationwide initiative, the "Living with Rare Disease: 2024 Bionews Patient Survey," to focus on the lived experiences of people with these rare conditions. The survey's insights into diagnostic and treatment journeys, and patients' daily life experiences, aim to enhance resources, support, and advocacy for all rare disease communities.



- Patients were recruited from BioNews' websites email lists, and social channels
- Survey was live Jan. 9-Feb. 13, 2024

#### **Overall Quality of Life**

Patients want more research funding, greater awareness, improved access to treatment, and better support systems.



## **Over 40** rare diseases were represented by sample.

#### Breakdown of those diagnosed patients:



likely to have these diseases.



#### Learn More

To view more survey details, including patient community opportunities and actionable solutions for pharmaceutical marketers and business leaders, contact Bionews SVP of Business Development Ethan Ash at <u>ethan.ash@bionews.com.</u>

# Diagnosis Journey

### **Opportunities**

- 🗹 Raise disease awareness
- Provide educational resources
- Promote online tools
- Improve communication channels
- Increase emotional support

#### **Time to Diagnosis**

On average, it took **4.7 years** from the onset of symptoms for patients to receive a diagnosis.

For half of patients, it took **3+ years** to be diagnosed.

Many patients are misdiagnosed before receiving the right diagnosis.

### **Gender Differences in Diagnosis**



5.2 years 3.2 years female male

Females experienced a longer diagnostic journey than males.

Females took an average of **5.2 years** to be diagnosed, compared to **3.2 years** for males. Females were significantly more likely to be misdiagnosed before their current diagnosis (55% vs. 44% for males).

#### **Physician Experience**

Diagnosed patients saw an average of **4.3 physicians** related to their symptoms before receiving a diagnosis.



**72%** of diagnosed patients ultimately were diagnosed by a specialist.



63% of diagnosed patients were satisfied with the communication they had with their healthcare providers during their diagnosis journeys.

### **Difficulties Faced**



**36%** had problems related to finance/insurance, including out-of-pocket expenses for medications, doctors, testing, travel costs, and lost wages



**40%** faced access issues including lack of testing or specialists near them



**32%** dealth with long wait times for testing/specialists

**33%** emo

# **33%** faced lack of emotional support

#### **Online Resources**

**67% of patients used online resources** to aid in their diagnosis, including search engines, health information sites, online patient communities, and patient advocacy websites.

Online resources helped patients identify symptoms, learn about treatment options, and connect with other patients.

#### **Need for Increased Awareness**

**80%** of patients say lack of knowledge about rare diseases was a hurdle in diagnosis. Women **(81%)** faced this challenge slightly more often than men **(76%)**.

# Treatment Journey

Gaps in treatment awareness and satisfaction: Many patients are unaware of available treatments, and a significant portion are dissatisfied with their current options, particularly female and younger patients.

#### **Opportunities**

- Increase awareness and availability of treatments
- Improve treatment satisfaction
- Develop patient support programs
- Address needs of specific patient groups

#### **Medication Burden**



40% of diagnosed patients are taking more than 6 medications, with an average of 5.4 medications.

# Lack of Awareness & availability of FDA-approved Treatments

21%

**1:5** diagnosed patients are not sure if there is an FDAapproved treatment for their condition. Females are significantly less likely to be aware of treatments than males.

#### Satisfaction with FDA-approved Treatments



#### Complementary Medications and Support:

Many **(59%)** patients use medications to manage symptoms and improve their quality of life, in addition to FDAapproved treatments. **65%** of patients are modifying their lifestyle while **31%** are using complementary and alternative therapies.

### **Total Treatment Experience**



61% of diagnosed patients are satisfied with their current comprehensive treatment plan.

## **Medication Switching**



Almost half of patients **(48%)** are open to switching medications within the next year.

Common reasons for switching include: ineffectiveness of current treatment, physician recommendation, or a new drug approval.

#### **Gender differences**

Female patients say they are more likely to switch medications within the next year.



Male patients are more likely to say they'd switch because a new drug is approved or expected to be approved.

31% of male vs. 19% of female diagnosed patients.

# Daily Life Experiences & Caregiving Relationship

### **Opportunities**

- Develop patient support programs
- Support for physical limitations among all patients
- Bolstering emotional and mental health among younger patients
- Supporting patients to better engage in daily and social lives/activities

Tailor resources to specific patient groups

#### Impact of disease on daily activities



## Caregiving

**About 3 in 10 patients** have a dedicated caregiver, with most receiving care from family/friends rather than professionals.

Cost, availability, and finding the right fit are challenges faced by patients who need caregiving services.

# Bionews' full range of available, condition-specific insights: Survey Respondent Sample Sizes

- Amyotrophic lateral sclerosis 264
- ANCA-associated vasculitis 243
  - Angioedema 38
- Atypical hemolytic uremic syndrome 25
  - Charcot-Marie-Tooth disease 235
    - Cold agglutinin disease 96
      - Cushing's disease 73
        - Cystic fibrosis 73
    - Ehlers-Danlos syndrome 627
      - Fabry disease 36
  - Familial amyloid polyneuropathy 12
    - Friedreich's ataxia 27
      - Hemophilia 16
    - Huntington's disease 36
    - Hypoparathyroidism 47
- Lambert-Eaton myasthenic syndrome 32
  - Muscular dystrophy 83
    - Myasthenia gravis 426
      - Myeloma 121
- Neuromyelitis optica spectrum disorder 21
  - Other 193
  - Pompe disease 9
    - Porphyria 21
  - Pulmonary fibrosis 424
  - Pulmonary hypertension 172
    - Sarcoidosis 382
    - Scleroderma 548
    - Sickle cell disease 32
  - Spinal muscular atrophy **30** 
    - N =4372

#### **About Bionews**

Bionews is a health media company focused on rare diseases and rare patient experiences. We provide an insider's view of disease and treatment news, condition management information, and community for more than 60 diseases. As a fierce champion of the rare voice, BioNews content is designed to reach, engage, and elevate even the smallest patient populations. We are the only rare news and information property in the U.S. People turn to us for timely treatment news, management tips, community support, and to identify clinical trial opportunities that are the right match for them.

#### Learn more

To view more survey details, including patient community opportunities and actionable solutions for pharmaceutical marketers and business leaders, contact Bionews SVP of Business Development Ethan Ash at ethan.ash@bionews.com.